Baseline, CLL, and transplant characteristics in this cohort of patients with CLL who underwent alloHCT
| Baseline characteristics . | Proportion, % or median (range) . | No. with available data (total N = 65) . |
|---|---|---|
| Age at CLL diagnosis, y | 50 (33-68) | 63 |
| Sex, male | 78 | 65 |
| Race, white | 92 | 64 |
| CLL characteristics | ||
| Cytogenetic and molecular characteristics | ||
| TP53 mutation | 51 | 45 |
| Del17p | 44 | 61 |
| Del11q | 33 | 57 |
| Complex karyotype | 50 | 42 |
| IGVH unmutated | 90 | 50 |
| CLL disease burden | ||
| Elevated LDH prior to alloHCT | 31 | 48 |
| CLL status prior to alloHCT | 65 | |
| CR | 26 | |
| CR with U-MRD, residual MRD, unknown MRD status | n = 2, 9, 6 | |
| PR | 66 | |
| SD | 5 | |
| PD | 3 | |
| Transplant characteristics | ||
| Age at alloHCT, y | 60 (38-69) | 65 |
| HCT-CI (0, 1-2, ≥3) | 38, 37, 25 | 64 |
| Donor | 64 | |
| Related | 34 | |
| Unrelated | 66 | |
| HLA match (A, B, C, DRB1) | 64 | |
| Matched (8/8) | 83 | |
| Mismatched (7/8) | 11 | |
| Haplo (4/8) | 6 | |
| CMV serology | 63 | |
| Patient positive/Donor negative | 33 | |
| All other CMV serology | 67 | |
| Conditioning regimen | 64 | |
| Myeloablative conditioning | 5 | |
| Reduced-intensity conditioning | 95 | |
| GVHD prophylaxis regimen | 63 | |
| Calcineurin inhibitor and methotrexate ± other | 84 | |
| Calcineurin inhibitor and MMF ± other | 3 | |
| Calcineurin inhibitor and sirolimus ± other | 5 | |
| Posttransplant cyclophosphamide | 5 | |
| Other | 3 |
| Baseline characteristics . | Proportion, % or median (range) . | No. with available data (total N = 65) . |
|---|---|---|
| Age at CLL diagnosis, y | 50 (33-68) | 63 |
| Sex, male | 78 | 65 |
| Race, white | 92 | 64 |
| CLL characteristics | ||
| Cytogenetic and molecular characteristics | ||
| TP53 mutation | 51 | 45 |
| Del17p | 44 | 61 |
| Del11q | 33 | 57 |
| Complex karyotype | 50 | 42 |
| IGVH unmutated | 90 | 50 |
| CLL disease burden | ||
| Elevated LDH prior to alloHCT | 31 | 48 |
| CLL status prior to alloHCT | 65 | |
| CR | 26 | |
| CR with U-MRD, residual MRD, unknown MRD status | n = 2, 9, 6 | |
| PR | 66 | |
| SD | 5 | |
| PD | 3 | |
| Transplant characteristics | ||
| Age at alloHCT, y | 60 (38-69) | 65 |
| HCT-CI (0, 1-2, ≥3) | 38, 37, 25 | 64 |
| Donor | 64 | |
| Related | 34 | |
| Unrelated | 66 | |
| HLA match (A, B, C, DRB1) | 64 | |
| Matched (8/8) | 83 | |
| Mismatched (7/8) | 11 | |
| Haplo (4/8) | 6 | |
| CMV serology | 63 | |
| Patient positive/Donor negative | 33 | |
| All other CMV serology | 67 | |
| Conditioning regimen | 64 | |
| Myeloablative conditioning | 5 | |
| Reduced-intensity conditioning | 95 | |
| GVHD prophylaxis regimen | 63 | |
| Calcineurin inhibitor and methotrexate ± other | 84 | |
| Calcineurin inhibitor and MMF ± other | 3 | |
| Calcineurin inhibitor and sirolimus ± other | 5 | |
| Posttransplant cyclophosphamide | 5 | |
| Other | 3 |
MMF, mycophenolate mofetil.